Clinical Trial

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

Study acronym: F-Sharp

Active, Not Recruiting

Record status

This record was last updated September 24, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Summary

This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy. The study will examine the safety and efficacy of the treatment. The type of radiation that participants in this research will receive is targeted directly at the areas of the prostate where recurrent disease is evident, while avoiding treatment of the normal appearing prostate. This involves the placement of a radioactive material in the affected area of the prostate temporarily, where it remains for a short period of time, and then is subsequently removed using a minimally invasive technique called HDR Brachytherapy.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2017-10-16; most recent amendment 2025-09-19.

Status change: Recruiting → Active, Not Recruiting 2025-09-19

Trial Details

NCT Number	NCT03312972
Lead Sponsor	Loyola University
Conditions	Locally Recurrent Prostate Cancer
Enrollment	50 participants
Start Date	2017-08-28
Primary Completion	2026-03-31 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-24